Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digital Health And Reimbursement Issues Divide Glucose Monitoring Market

Executive Summary

Innovative technology from companies such as Google offers the promise of new digital health options in the glucose monitoring market, while drastic reimbursement cuts affecting existing meters and supplies in the US are taking a noticeable toll on the major players already operating in the field. These competing factors have created a dichotomy characterized by opportunity on one side and uncertainly on the other, and that is forcing some competitors to re-think their business strategies.

You may also be interested in...



Google Moves Further Into Medical Device Space

Google is making further inroads into the medical device space with deals designed to move the company’s two highly touted eyewear products into use by medical professionals. For Google’s smart contact lens, the company has partnered with Alcon to develop a glucose monitoring system, while Google Glass has become part of a project that will allow ambulance teams to transmit live views of patients in transit.

The Artificial Pancreas: A Race To The Finish

The first fully functional artificial pancreas for patients with diabetes could be ready for regulatory submission in the next few years. Medtronic has achieved notable success in this area to date, but positive clinical studies have put J&J in a good position as well, and the medical community is watching closely as the major developments in this groundbreaking endeavor continue to move forward.

The Artificial Pancreas: A Race To The Finish

The race to develop a fully functional artificial pancreas for patients with diabetes is entering the later stages, and the first such device could be ready for regulatory submission in the next few years. Medtronic has achieved notable success in this area to date, but positive clinical studies have put J&J in a good position as well, and the medical community is watching closely as the major developments in this groundbreaking endeavor continue to move forward.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel